News
Videos
Conferences
Events
Resources
Subscribe

|Videos|September 27, 2017

Immunotherapy in Bladder Cancer

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dr. Patrick J. Hensley

What Are Non-Muscle Invasive Bladder Cancer and its Treatment Options?

BySpencer Feldman

October 9th 2025

FDA sign image

All FDA Oncology Approvals From September 2025

BySpencer Feldman

October 1st 2025

Frank Garred, 77, completed TAR-200 treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.

Positive Experience With TAR-200 for Recurrent Bladder Cancer

September 30th 2025

Dr. Patrick J. Hensley

How Individual Risk Factors May Guide Bladder Cancer Treatment

ByDr. Patrick J. Hensley

September 29th 2025

Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment: © stock.adobe.com.

What to Know About Early-Stage Urothelial Carcinoma

September 26th 2025

Trending on CURE

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma

What Are Non-Muscle Invasive Bladder Cancer and its Treatment Options?

Body Image and Sexual Health Challenges After Breast Cancer

Minimally Invasive Kidney Cancer Treatments Boosts Patient Recovery

Finding Hope Amidst a Lung Cancer Diagnosis

© 2025 MJH Life Sciences^®

All rights reserved.